From the Department of Pediatrics, Children's Mercy-Kansas City, Kansas City, Missouri.
University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.
Pediatr Infect Dis J. 2021 Apr 1;40(4):295-299. doi: 10.1097/INF.0000000000002988.
Parechovirus A type 3 (PeV-A3) is associated with central nervous system infection in young infants. There are limited data regarding long-term outcomes, mostly reported from Australia and European populations. The objective of this study was to assess frequency of neurodevelopmental impairment (NDI) following PeV-A3 infection in our US cohort.
Infants hospitalized during the 2014 outbreak with laboratory-confirmed PeV-A3 infection were evaluated with medical history, neurologic examination, parental completion of Ages and Stages Questionnaire and developmental assessment using Bayley Scales of Infant and Toddler Development, Third Edition cognitive, motor and language quotients. Determination of NDI was based on published criteria. Relationship of severity of PeV disease to outcome measures was determined using Fisher exact, χ2 and Mann-Whitney U test as appropriate.
Nineteen children, term gestation, were evaluated at ~3 years of age; PeV-A3 illness was uncomplicated for 6 (32%), complex, non-neurologic for 9 (47%) and encephalitis/seizures for 4 (21%). No differences were noted in mean Bayley Scales of Infant and Toddler Development, Third Edition quotients between infants by clinical presentation. Quotients for all were within 1 SD of population norms. Two (11%) children had mild NDI; 1 with mild cerebral palsy. Ages and Stages Questionnaire results included 11% at referral level and 37% suspect concern. Parents of 6 (32%) noted behavior concerns. These findings were unrelated to severity of the PeV-A3 illness.
Parent concerns were identified frequently following infant PeV-A3 disease. Eleven percent had neurodevelopmental impairment at 3 years of age. Severity at presentation did not correlate with adverse childhood outcomes. Longitudinal developmental monitoring following infantile PeV-A3 disease is warranted.
肠道病毒 A 型 3 型(PeV-A3)与婴幼儿中枢神经系统感染有关。关于长期结果的数据有限,主要来自澳大利亚和欧洲人群。本研究的目的是评估我们美国队列中 PeV-A3 感染后神经发育障碍(NDI)的发生率。
在 2014 年爆发期间住院并经实验室确诊为 PeV-A3 感染的婴儿,通过病史、神经系统检查、父母完成年龄与阶段问卷以及使用贝利婴幼儿发展量表第三版进行认知、运动和语言商数的发育评估进行评估。根据已发表的标准确定 NDI。使用 Fisher 精确检验、χ2 和 Mann-Whitney U 检验确定 PeV 疾病严重程度与结局测量之间的关系。
19 名足月婴儿在~3 岁时进行了评估;6 名(32%)PeV-A3 疾病无并发症,9 名(47%)为复杂非神经疾病,4 名(21%)为脑炎/癫痫发作。根据临床表现,婴儿的贝利婴幼儿发展量表第三版商数无差异。所有婴儿的商数均在人群正常值的 1 SD 范围内。2 名(11%)儿童有轻度 NDI;1 名有轻度脑瘫。年龄与阶段问卷结果包括 11%的转诊水平和 37%的可疑关注。6 名(32%)儿童的父母注意到行为问题。这些发现与 PeV-A3 疾病的严重程度无关。
婴儿 PeV-A3 疾病后,父母经常表示担忧。11%的儿童在 3 岁时出现神经发育障碍。发病时的严重程度与不良儿童结局无关。需要对婴儿 PeV-A3 疾病后进行纵向发育监测。